Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.

PURPOSE Standard therapy for multiple myeloma consists of cytotoxic chemotherapy plus glucocorticoids. Interferon (IFN) alfa maintenance is reported to prolong chemotherapy-induced remissions and survival. This study evaluates induction chemotherapy, glucocorticoids, and interferon maintenance in myeloma. PATIENTS AND METHODS Five hundred twenty-two previously untreated myeloma patients were randomized to three chemotherapy regimens with differing glucocorticoid intensities. Patients who achieved remission were randomized to receive IFN or observation until relapse. Patients who failed to respond to chemotherapy received IFN alfa plus dexamethasone (DEX). RESULTS Five hundred nine patients were eligible for induction chemotherapy. Chemotherapy with higher dose-intensity glucocorticoids yielded higher response rates and improved survival (P = .02 for the three-group comparison; P < .05 for each higher glucocorticoid arm v vincristine, melphalan, cyclophosphamide, and prednisone alternating with vincristine, carmustine [BCNU], doxorubicin, and prednisone [VMCP/VBAP]). One hundred ninety-three patients who achieved remission were randomized to receive IFN alfa 3 MU three times weekly or observation. IFN was not superior to observation for relapse-free (P = .95) or overall survival (P = .39) from start of maintenance. Eighty-eight induction failures received 5 MU of IFN three times weekly plus DEX. Patients who received IFN/DEX had a median survival duration of 48 months from start of IFN/DEX. CONCLUSION Higher-dose glucocorticoids increases frequency of response to chemotherapy and prolong survival in myeloma. IFN maintenance with the dose schedule used in this trial did not prolong relapse-free or overall survival. We cannot exclude a small effect of IFN, as most individual trials do not have sufficient statistical power. Meta-analysis of randomized trials evaluating IFN maintenance in myeloma might be of value. While IFN appeared ineffective, addition of higher-dose glucocorticoids improved outcome in myeloma.

[1]  C. Schiffer,et al.  A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Gahrton,et al.  Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden , 1993 .

[3]  A. Belch,et al.  Are the current criteria for response useful in the management of multiple myeloma? , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[5]  B. Barlogie,et al.  Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors , 1990 .

[6]  B. Barlogie,et al.  Primary dexamethasone treatment of multiple myeloma. , 1992 .

[7]  H. Asaoku,et al.  Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption. , 1990, Blood.

[8]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[9]  M. Gobbi,et al.  [Allogeneic bone marrow transplantation in multiple myeloma]. , 1991, Haematologica.

[10]  M. Fey,et al.  Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. , 1992, Blood.

[11]  H. Deicher,et al.  Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group. , 1990, Onkologie.

[12]  B. Cheson,et al.  Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[14]  J. Westin.  Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study. , 1991, Seminars in oncology.

[15]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[16]  F. Mandelli,et al.  Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. , 1990, The New England journal of medicine.

[17]  B. Barlogie,et al.  Effective treatment of advanced multiple myeloma refractory to alkylating agents. , 1984, The New England journal of medicine.